Lugui Qiu

机构：Tianjin University of Technology, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, National Clinical Research, Magbro Healthcare (India), Tianjin Hospital, Institute of Hematology & Blood Diseases Hospital, Southeast University · ORCID：0000-0002-9948-1662

发表论文 335 篇 · 总被引 2169 次 · h-index 26

代表论文

• Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study (2025 · Journal of Clinical Oncology · 被引 4)
• Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor (2025 · Blood · 被引 2)
• Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) (2025 · Blood · 被引 1)
• QLS4131, a next-generation GPRC5D×BCMA×CD3 trispecific T-cell engager, in patients with relapsed/refractory multiple myeloma (RRMM): Initial results of a first-in-human Phase Ⅰa study (2025 · Blood · 被引 1)
• MBS314, a GPRC5DxBCMAxCD3 trispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results from a Phase 1 dose escalation study (2025 · Blood · 被引 1)
• Supplementary Figure S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial (2025)